Evidence map›Paper›PMID 40049206›Full record

ArticleThe Lancet. Oncology2025

Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.

Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum, James Welsh, Heiko Enderling, Jonathan D Schoenfeld, Joshua D Brody, Heather M McGee and 38 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Materials today. Bio · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. In Response.JTO clinical and research reports · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors.

Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: zmorris@humonc.wisc.edu.
Sandra DemariaWeill Cornell Medicine, Department of Radiation Oncology, New York, NY, USA.
Arta M MonjazebUC Davis Health, Department of Radiation Oncology, Sacramento, CA, USA.
Silvia C FormentiWeill Cornell Medicine, Department of Radiation Oncology, New York, NY, USA.
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA.
James WelshDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Heiko EnderlingDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Jonathan D SchoenfeldBrigham and Women's Hospital-Dana-Farber Cancer Institute, Boston, MA, USA.
Joshua D BrodyIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Heather M McGeeDepartment of Radiation Oncology and Department of Immuno-Oncology, City of Hope, Duarte, CA, USA.
Michele MondiniGustave Roussy, Université Paris-Saclay, INSERM U1030, Villejuif, France.
Michael S KentDavis School of Veterinary Medicine, University of California, Davis, CA, USA.
Kristina H YoungEarle A Chiles Research Institute, Portland, OR, USA.
Lorenzo GalluzziCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Sana D KaramDepartment of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Willemijn S M E TheelenDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Joe Y ChangDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Mai Anh HuynhBrigham and Women's Hospital-Dana-Farber Cancer Institute, Boston, MA, USA.
Adi DaibDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Sean PitrodaDepartment of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA.
Caroline ChungDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Raphael SerreAix Marseille University, SMARTc Unit, Inserm S 911 CRO2, Marseille, France.
Clemens GrassbergerFred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
Jie DengDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Quaovi H SodjiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Anthony T NguyenCedars-Sinai Medical Center, Department of Radiation Oncology, Los Angeles, CA, USA.
Ravi B PatelDepartment of Radiation Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA.
Simone KrebsMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medicine, Department of Radiology, New York, NY, USA.
Anusha KalbasiDepartment of Radiation Oncology, Stanford Cancer Institute, Stanford School of Medicine, Stanford, CA, USA.
Caroline KerrDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Claire Vanpouille-BoxWeill Cornell Medicine, Department of Radiation Oncology, New York, NY, USA.
Logan VickDepartment of Dermatology, University of California Davis School of Medicine, Sacramento, CA, USA.
Todd A AguileraUT Southwestern Medical Center, Dallas, TX, USA.
Irene M OngDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Fernanda HerreraLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Hari MenonDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
DeeDee SmartRadiation Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Jalal AhmedIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Robyn D GartrellDepartment of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA; Department of Oncology, Division of Pediatric Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Christina L RolandDepartment of Thoracic Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Fatemeh FekrmandiDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Binita ChakrabortyDepartment of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Eric H BentDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tracy J BergDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Samir KhleifLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Andrew G SikoraDepartment of Head and Neck Surgery, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Lawrence FongFred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Project 3: Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers.P01CA261669 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TITT, UWE · 2021 to 2025
$14.0M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2020 to 2024
$12.5M
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9M
Integrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Mechanisms of Exosome Driven Immunoregulation of Cancer ProgressionU01CA244452 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLELLOCH, ROBERT, FONG, LAWRENCE · 2019 to 2022
$4.1M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancerU01DE028233 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANNAPRAGADA, ANANTH V, SIKORA, ANDREW · 2018 to 2022
$3.9M
Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten captureR37CA262557 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Simone Krebs · 2021 to 2026
$3.4M
The Impact of Obesity on Radiotherapy Anti-Tumor EffectsR01CA240751 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Arta Monir Monjazeb · 2022 to 2026
$2.9M
Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapyU01CA244100 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ENDERLING, HEIKO, PILON-THOMAS, SHARI · 2020 to 2025
$2.6M
NCI NIH HHS F30 CA268780NCI NIH HHS P01 CA250972NCI NIH HHS P01 CA261669NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA240751NCI NIH HHS R01 CA283953NCI NIH HHS R21 CA248118NCI NIH HHS R37 CA262557NCI NIH HHS U01 CA233100NCI NIH HHS U01 CA233102NCI NIH HHS U01 CA244100NCI NIH HHS U01 CA244452NCI NIH HHS U01 CA280849NCI NIH HHS U24 CA232979NIDCR NIH HHS U01 DE028233NIGMS NIH HHS T32 GM140935
6 · The paper itself

Abstract

Radiotherapy both promotes and antagonises tumour immune recognition. Some clinical studies show improved patient outcomes when immunotherapies are integrated with radiotherapy. Safe, greater than additive, clinical response to the combination is limited to a subset of patients, however, and how radiotherapy can best be combined with immunotherapies remains unclear. The National Cancer Institute-Immuno-Oncology Translational Network-Society for Immunotherapy of Cancer-American Association of Immunology Workshop on Combining Immunotherapy with Radiotherapy was convened to identify and prioritise opportunities and challenges for radiotherapy and immunotherapy combinations. Sessions examined the immune effects of radiation, barriers to anti-tumour immune response, previous clinical trial data, immunological and computational assessment of response, and next-generation radiotherapy-immunotherapy combinations. Panel recommendations included: developing and implementing patient selection and biomarker-guided approaches; applying mechanistic understanding to optimise delivery of radiotherapy and selection of immunotherapies; using rigorous preclinical models including companion animal studies; embracing data sharing and standardisation, advanced modelling, and multidisciplinary cross-institution collaboration; interrogating clinical data, including negative trials; and incorporating novel clinical endpoints and trial designs.

Indexed as

ImmunotherapyNeoplasmsRadiotherapyTranslational Research, BiomedicalAnimalsCombined Modality TherapyHumansNational Cancer Institute (U.S.)United States

Identifiers

PMID40049206
PMCPMC12758888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.